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Abstract  
Novel bifunctional pyrrolidine-based organocatalysts for the asymmetric Michael 
addition of carbonyl compounds to nitroolefins have been synthesised from 
homoallylimines, which are easily obtained from (R)-glyceraldehyde as chiral 
precursor. Under optimal reaction conditions these bifunctional organocatalysts 
showed a high catalytic efficiency (almost quantitative yield in most cases) and 
stereoselectivity in the Michael addition reactions of a variety of aldehydes (up to 
98:2 dr and 97% ee) and ketones (up to 98:2 dr and 99% ee) to nitroolefins. 
 
Introduction 
Nowadays there is no doubt about the preeminent role of organocatalysis in 
enantioselective synthesis. The use of simple chiral organic molecules as catalysts 
has provided new and convenient synthetic methodologies to obtain a wide variety of 
chiral building blocks and pharmaceutical products1 and these methods have 
transformed the field of asymmetric catalysis.2 
Among the different organocatalysts developed for use in enantioselective synthesis, 
proline and its derivatives have proven to be especially useful in reactions that take 
place through the formation of enamine intermediates3 and, in combination with other 
functional groups, they have provided bifunctional organocatalysts that are capable 
of efficiently promoting a wide array of asymmetric processes.4 
One particularly useful reaction that can be promoted by pyrrolidine-based 
organocatalysts is the addition of carbonyl compounds to nitroolefins. The reaction 
provides γ-nitrocarbonyl compounds with two contiguous stereocentres and these 
compounds are key precursors for the synthesis of relevant bioactive molecules.5 
Since the pioneering reports of List6 and Barbas7 on this subject a number of efficient 
catalysts have been designed and applied to this addition reaction.8 In spite of the 
progress made in this area, interest in the design and development of new and 
efficient chiral organocatalysts for this and other important chemical transformations 
still continues. 
As a part of our programme aimed at developing new, easily accessible and tunable 
organocatalysts from the chiral pool,9 we have now focused on the synthesis of new 
bifunctional organocatalysts with the privileged pyrrolidine motif from chiral imines 
derived from (R)-glyceraldehyde and their application to the enantioselective Michael 
addition of carbonyl compounds to nitroolefins. 
 
Results and discussion 
We have previously described that chiral pyrrolidines with a bulky tunable 2,2-
disubstituted-1,3-dioxolan-4-yl moiety at C2 are effective organocatalysts in the 
asymmetric Michael addition of aldehydes to nitroolefins.9b It has also been reported 
the beneficial effect on catalytic performance of the presence of the appropriate 
group at the 4 position of the pyrrolidine ring in pyrrolidine-based silyl ether 
organocatalysts.10 Bearing these results in mind, we decided to prepare new 
bifunctional organocatalysts with the general structure depicted in Figure 1 with the 
objective of obtaining improved organocatalysts. These chiral templates combine a 
2,2-disubstituted-1,3-dioxolan-4-yl moiety at the 2-position of the pyrrolidine to 
provide a bulky environment and a different shielding of the two faces of the 
intermediate enamine and a sulfonamide group at the 4 position of the ring that is 
capable of interacting with the reagent and directing the attack. 
We presumed that these new catalysts could be prepared starting from homoallylic 
amine 1, which is easily obtained on a multigram scale from N-benzyl imines derived 
from (R)-glyceraldehyde acetonide according to our previously described 
procedure.11 
 
 
 
 
Fig. 1 General structure of new pyrrolidine-based bifunctional organocatalysts 
 
It has been reported12 that iodine-mediated cyclisation of homoallylamines at room 
temperature leads to the formation of 2,4-azetidines that are prone to isomerisation 
to 2,4-pyrrolidines upon heating. Iodocyclisation of homoallylamine 1 was chosen to 
construct the pyrrolidine ring functionalised at C4. After some experimentation the 
best results were obtained by reaction of homoallylic amine 1 with iodine (4 equiv.) 
and sodium hydrogen carbonate (5 equiv.) in toluene at room temperature for 24 h 
followed by heating in acetonitrile at 40 °C for 2 h. Reaction under these conditions 
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led to the formation of a 60/40 diastereomeric mixture of cis- and trans-pyrrolidines 
2c/2t in 62% isolated yield. Nucleophilic displacement of iodine by azide through the 
treatment of 4-iodopyrrolidines 2c/2t with sodium azide in DMF at 90 °C provided 4-
azidopyrrolidines 3c/3t as a 40/60 mixture of cis and trans diastereoisomers. The 
diastereomeric mixture of azidopyrrolidines 3c/3t was reduced to the corresponding 
cis- and trans-4-aminopyrrolidines 4c/4t by hydrogenation over Pd/C in ethanol. The 
reaction sequence to prepare 4-aminopyrrolidines 4c/4t from homoallylamine 1 is 
shown is Scheme 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1 Synthesis of cis- and trans-4-aminopyrrolidines 4c/4t 
 
The organocatalysts OC1 and OC2 were prepared by treating the diastereomeric 
mixture of cis- and trans-4-aminopyrrolidines 4c/4t with trifluoromethanesulfonic 
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anhydride and triethylamine to afford the corresponding triflates 5c and 5t, which 
were easily isolated by column chromatography. Subsequent N-debenzylation was 
achieved by exposure of the isolated triflates to molecular hydrogen in the presence 
of Pd/C as a catalyst. In a similar way, tosylation of the 4c/4t diastereomeric mixture 
with p-toluenesulfonyl chloride in the presence of triethylamine and subsequent 
deprotection by hydrogenolysis of isolated tosylates 6c and 6t provided access to 
organocatalysts OC3 and OC4 (Scheme 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2 Synthesis of organocatalysts OC1–OC4 
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The structure and stereochemistry of major 4-iodopyrrolidine 2c were established on 
the basis of NMR data and a NOESY experiment (Figure 2). In the NOESY spectrum 
of compound 2c clear cross-peaks were observed between the H2 and H4 
resonances. These cross-peaks clearly indicate a close spatial disposition, which is 
only possible if these two nuclei are in a cis disposition. In addition, the 
stereochemistry of minor tosylate 6c was determined as (2S,4S) by X-ray diffraction 
analysis. These results allowed the stereochemistry of the obtained compounds to be 
unambiguously established. 
 
 
 
 
 
Fig. 2 Diagnostic nOe for the determination of the stereochemistry of 2c 
Initial screening of the catalytic properties of the sulfonamides OC1–OC4 for the 1,4-
addition between trans-β-nitrostyrene and pentanal in toluene at room temperature 
and in the presence of 10 mol% of catalyst (Table 1) showed that a trans disposition 
of substituents was necessary for efficient catalysis. With sulfonamides OC-2 and 
OC-4, which have a cis disposition between the sulfonamide and the bulky 
substituent, the reaction under these conditions proceeded to give a quite poor yield, 
whereas sulfonamides OC-1 and OC-3, which have a trans disposition between the 
two substituents, promoted the reaction well, with OC-3 being more enantioselective 
than OC-1 (93% ee vs 87% ee). As far as the reaction medium is concerned, the 
best results were obtained in toluene.  
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Table 1 Initial screening for the Michael addition of pentanal to trans β-nitrostyrene.a 
 
 
 
 
___________________________________________________________________ 
Entry Catalyst Solvent T Time  Yieldb syn/anti b eec syn  
       (%)      (%) 
___________________________________________________________________ 
1 OC1 toluene rt 24 h 100 94/6 87 
2 OC2 toluene rt  7 d 11 85/15 75 
3 OC3 toluene rt  24 h 100 94/6 93 
4 OC4 toluene rt  7 d 43 89/11 81 
5 OC3 CF3Ph rt  24 h 100 87/13 82 
6 OC3 CHCl3 rt  24 h 99 87/13 69 
7 OC3 THF rt  24 h 13 72/28 49 
8 OC3 MeCN rt  24 h 36 68/32 44 
9 OC3 EtOH rt  24 h 70 61/39 33 
10 OC3 H2O rt  24 h 85 93/7 86 
11 OC3 brine rt  24 h 100 87/13 72 
12 OC3 toluene 0 ºC  3 d 100 95/5 91 
13 OC3 CF3Ph 0 ºC 5 d 100 90/10 87 
14 OC3d toluene rt  3 d 100 95/5 92 
___________________________________________________________________ 
OHC NO2
Pr
Ph
solvent, T
OC (10 mol%)
Pr
OHC
+
Ph
NO2
9a
a All reactions were carried out under the following conditions: aldehyde (0.33 mmol), 
tosylamine (0.3 mmol), BF3·OEt2 (0.33 mol), dry solvent (5 mL), room temperature, 
20 h, under Ar. b Determined from the crude reaction mixture by 1H NMR using 1,3,5-
trimethoxybenzene as internal standard. 
 
It is worth mentioning that OC-3 is an active and highly stereoselective 
organocatalyst that works in aqueous media, although the stereoselectivity values 
were lower than those observed in toluene. A decrease in the reaction temperature 
did not improve the results obtained on working at room temperature and extended 
the reaction time. The catalyst loading could be decreased and the 
diastereoselectivity and enantioselectivity levels were maintained, although a longer 
reaction time was required to achieve a similar reaction yield. 
Based on the results described above, we selected p-toluenesulfonamide OC3 as the 
organocatalyst and explored the scope of the reaction with other aldehydes and 
nitroolefins. The reactions were carried out at room temperature in the presence of 
10 mol% of catalyst and using toluene as solvent. The results are summarised in 
Table 2. Under these reaction conditions most Michael adducts were obtained in 
almost quantitative yield with very good diastereoselectivity (syn/anti 89/11–98/2) and 
high enantioselectivity (75–97% ee). With 3-methylbutanal as substrate the reactions 
took up to 7 days to reach completion. In order to shorten reaction time p-
toluenesulfonic acid was added to the reaction medium as Brønsted acid co-
catalysts.13 The presence of this additive improved the catalytic activity but was 
detrimental to the enantio- and diastereoselectivity. 
  
Table 2 Scope of the Michael addition of aldehydes to trans-β-nitroolefins using 
catalysts OC3.a 
 
 
 
___________________________________________________________________ 
Entry Product R1 R2 Time  Yieldb syn/anti b eec syn 
       (%)      (%) 
___________________________________________________________________ 
1 9a nPr Ph 24 h 100 94/6 93 
2 9b Bn Ph 10 h 100 95/5 88 
3 9c Et Ph 24 h 100 91/9 91 
4 9d Me Ph 24 h 100 95/5 91 
5 9e nHx Ph 24 h 100 93/7 93 
6 9f CH2=CH(CH2)7 Ph 26 h 100 97/3 92 
7 9g iPr Ph 7 d 100 98/2 97 
8d 9g iPr Ph 4 d 100 85/15 95 
9e 9h nPr 2-furyl  24 h 98 89/11 75 
10 9i nPr    4-MeOC6H4 36 h 100 93/7 89 
11 9j nPr    4-MeC6H4 24 h 100 93/7 92 
12 9k nPr    4-ClC6H4 24 h 100 92/8 91 
13 9l nPr    4-BrC6H4 24 h 99 94/6 92 
14 9m nPr    3-BrC6H4 24 h 100 95/5 92 
15 9n nPr    2-BrC6H4 24 h 100 95/5 92 
___________________________________________________________________ 
OHC NO2
R1
R2
toluene, rt
OC3 (10 mol%)
R1
OHC
+
R2
NO2
9a-9n
a Reaction performed using 0.2 mmol of nitroolefin, 0.4 mmol of aldehyde, 10 mol% 
of OC3, in toluene (2 mL) at room temperature. b Determined from the crude reaction 
mixture by 1H NMR spectroscopy using 1,3,5-trimethoxybenzene as internal 
standard. c Determined by chiral HPLC. d Reaction performed using 0.02 mmol of p-
nitrobenzoic acid as additive. e Reaction was performed in the absence of light. 
 
A second set of experiments was conducted using new bifunctional organocatalysts 
OC1 and OC3 to promote 1,4-addition between trans-β-nitrostyrene and ketones 
(Table 3). The preliminary results obtained in the reaction of cyclohexanone and 
trans-β-nitrostyrene showed that in this case trifluoromethanesulfonamide OC1 was 
the most active and enantioselective organocatalyst and that trifluoromethyl benzene 
was the best solvent. The use of 10 mol% of OC1 in trifluoromethyl benzene at room 
temperature gave a nearly quantitative yield of the corresponding Michael adduct 10a 
in 48 h. The catalyst gave high diastereoselectivity in favour of the syn-adduct (dr = 
97/3) and an excellent enantioselectivity (ee = 99%). A decrease in the reaction 
temperature did not improve these results and lowering the catalyst loading to 5 
mol% extended the reaction time and slightly decreased the diastereoselectivity. As 
before, organocatalyst OC-1 is active and highly stereoselective in aqueous media 
although the stereoselectivity values were lower than those observed in 
trifluoromethyl benzene. 
  
Table 3 Initial screening for the Michael addition of cyclohexanone to trans-β-
nitrostyrene.a 
 
 
 
___________________________________________________________________ 
Entry Catalysts Solvent T Time  Yieldb syn/anti b eec syn 
       (%)      (%) 
___________________________________________________________________ 
1 OC1 toluene rt 48 h 88 94/6 85 
2 OC3 toluene rt  3 d 88 94/6 74 
3 OC1 CF3Ph rt  48 h 100 97/3 99 
4 OC3 CF3Ph rt  3 d 84 93/7 91 
5 OC1 CHCl3 rt 48 h 92 96/4 74 
6 OC1 THF rt 48 h 2 > 98/2 79 
7 OC1 MeCN rt 48 h 100 95/5 95 
8 OC1 EtOH rt 48 h 21 96/4 70 
9 OC1 H2O rt 48 h 60 94/6 90 
10 OC1 brine rt 48 h 93 95/5 91 
11 OC1 CF3Ph 0 ºC 48 h 54 96/4 91 
12 OC3 CF3Ph 0 ºC  48 h 34 96/4 87 
13d OC1 CF3Ph rt 4 d 100 95/5 91 
___________________________________________________________________ 
NO2
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O O
10a
a Reaction performed using 0.2 mmol of β-nitrostyrene, 0.4 mmol of ketone and 10 
mol% of organocatalyst in the given solvent (2 mL).b Determined from the crude 
reaction mixture by 1H NMR spectroscopy using 1,3,5-trimethoxybenzene as internal 
standard. c Determined by chiral HPLC. d  Catalyst loading 5 mol%. 
 
Table 4 Scope of Michael addition of ketones to trans-β-nitroolefins using catalysts 
OC1.a 
 
 
___________________________________________________________________ 
Entry Product X R Time  Yieldb syn/anti b eec syn 
       (%)      (%) 
___________________________________________________________________ 
1 10a CH2 Ph 48 h 100 97/3 99 
2 10b O Ph 48 h 100 98/2 94 
3 10c AcN Ph 7 d 90 85/15 91 
4d 10d CH2     2-furyl  24 h 96 90/10 94 
5 10e CH2    4-MeOC6H4 7 d 100 96/4 84 
6 10f CH2    4-MeC6H4 48 h 100 98/2 96 
7 10g CH2    4-ClC6H4 24 h 100 95/5 98 
8 10h CH2    4-BrC6H4 48 h 100 96/4 93 
9 10i CH2    3-BrC6H4 36 h 100 95/5 93 
10 10j CH2    2-BrC6H4 36 h 100 97/3 94 
___________________________________________________________________ 
NO2
R
CF3Ph, rt
OC1 (10 mol%)
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10a-10j
a Reaction performed using 0.2 mmol of nitroolefin, 0.4 mmol of ketone, 10 mol% of 
OC1, in trifluoromethyl benzene (2 mL) at room temperature. b Determined from the 
crude reaction mixture by 1H NMR spectroscopy using 1,3,5-trimethoxybenzene as 
internal standard. c Determined by chiral HPLC. d Reaction was performed in the 
absence of light. 
 
The study was extended to other ketones as donor substrates using OC1 as the 
organocatalyst. Reactions were conducted at room temperature in the presence of 
10 mol% of catalyst and using trifluoromethylbenzene as solvent. Under these 
conditions cyclic ketones reacted with β-nitrostyrene derivatives to afford the 
corresponding Michael adducts in high yield (90–100%), diastereo- (syn/anti 85/15–
98/2) and enantioselectivity (84–99% ee) (Table 4). 
On the basis of previously reported studies8c,14 on the origin of regio- and 
stereoselectivity in Michael additions of pyrrolidine enamines we propose the 
following model to rationalise the observed stereochemical induction (Figure 3). 
The bifunctional pyrrolidine moiety reacts with the aldehyde to form the 
corresponding E-enamine intermediate. Due to the steric overcrowding imposed by 
the dioxolane moiety the preferential formation of the s-trans conformer A is 
expected. Hydrogen bonding interactions of the nitro group with the acidic site at the 
catalyst favours the formation of a rigid transition state in which the synclinal 
approach of the nitroolefin from the si-face of the enamine produce the 2R,3S 
stereoisomer. With the use of ketones as Michael donors is more stable the s-cis 
conformer of the E-enamine B. In this case the synclinal approach of the nitroolefin in 
the rigid hydrogen-bonded transition state takes place from the re-face of the 
enamine to produce the observed stereochemistry. 
  
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 Proposed model for Michael addition of aldehydes and ketones to nitroolefins 
catalysed by OC3 and OC1 
 
Conclusions 
In summary, novel pyrrolidine-based bifunctional organocatalysts bearing both a 
sulfonamide group and a sterically demanding group were synthesised from the 
chiral pool as a chiral source.  Iodine-mediated cyclisation of homoallylamines, 
obtained easily from (R)-glyceraldehyde imines, allowed the construction of the 
conveniently functionalised intermediate pyrrolidine from which sulfonamides of cis 
and trans configuration were prepared. Organocatalysts with a trans disposition of 
the two substituents exhibited excellent catalytic efficiency in the Michael addition 
reaction of aldehydes and ketones to trans-β-nitrostyrenes. In the reaction between 
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aldehydes and β-nitrostyrene derivatives the p-toluenesulfonamide OC3 was the 
most effective organocatalyst and provided Michael adducts with excellent 
stereoselectivities (up to 98:2 dr and 97% ee). The highest diastereoselectivities (up 
to 98/2 dr) and enantioselectivities (up to 99% ee) obtained using ketones as donor 
substrates were obtained with trifluoromethanesulfonamide OC1 as the catalyst. 
 
Experimental Section 
General Information.  
All reagents for reactions were of analytical grade and were used as obtained from 
commercial sources. All solvents were commercial grade and were purified prior to 
use when necessary. Homoallylamine 1 was prepared according to our previously 
described procedures.11 
Whenever possible the reactions were monitored by TLC. TLC analysis was 
performed on precoated silica gel polyester plates with an F254 indicator and products 
were visualised using ninhydrin, potassium permanganate or ethanolic 
phosphomolybdic acid solution followed by heating and UV light (254 nm). Column 
chromatography was performed using silica gel (Kiesegel 60, 230–400 Mesh). 
Melting points were determined in open capillaries using a Gallenkamp capillary 
melting point apparatus and are not corrected. FTIR spectra of oils were recorded as 
thin films on NaCl plates and FTIR spectra of solids were recorded as nujol 
dispersions on NaCl plates using a Thermo Nicolet Avatar 360 FT-IR 
spectrophotometer, νmax values expressed in cm–1 are given for the main absorption 
bands. Optical rotations were measured on a Jasco 1020 polarimeter at λ 589 nm 
and 25 °C in a cell with a 10 cm path length, [α]D values are given in 10–1 deg·cm2·g–
1 and concentrations are given in g/100 mL. 1H NMR and 13C NMR spectra were 
acquired on a Bruker AV-300 operating at 300 MHz for 1H NMR, and 75 MHz for 13C 
NMR or a Bruker AV-400 spectrometer operating at 400 MHz for 1H NMR, 376 MHz 
for 19F NMR and 100 MHz for 13C NMR.  Spectra were acquired at room temperature 
unless otherwise stated using a 5-mm probe. The chemical shifts (δ)  are reported in 
parts per million from tetramethylsilane with the solvent resonance as the internal 
standard.15 Coupling constants (J) are quoted in Hertz. The following abbreviations 
are used: s, singlet; d, doublet; q, quartet; dd, doublet of doublets; m, multiplet; bs, 
broad singlet; ddd, doublet of doublets of doublets, dddd, doublet of doublet of 
doublets of doublets. NOESY spectra were acquired in the phase sensitive mode 
with gradient pulses in the mixing time as 2048 x 256 hipercomplex files with 8 
transients for 256 time increments. A mixing time of 900 ms was used and 
processing was carried out using a sine-bell squared function shifted by p/2 and a 
states-TPPI method. Special precautions such as degassing of the sample were not 
taken. High resolution mass spectra were recorded using a Bruker Daltonics 
MicroToF-Q instrument from methanolic solutions using the positive electrospray 
ionisation mode (ESI+). HPLC analyses were carried out on a Waters HPLC system 
consisting of an M-600 low-pressure gradient pump, and an M-2996 photodiode 
array detector or a Waters HPLC system consisting of an M-600 low-pressure 
gradient pump, an M-2487 dual wavelength absorbance detector and the Waters 
Empower chromatography manager software. Commercially available 
polysaccharide chiral stationary phases Chiralcel® OD-H column, Chiralpak® AS-H 
column, Chiralpak® IA column and Chiralpak® IC column were used. 
 
  
(2S,4S)-1-Benzyl-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-4-iodopyrrolidine (2c) 
and (2S,4R)-1-benzyl-2-[(S)-2,2-dimethyl-1,3-dioxolan-4-yl]-4-iodopyrrolidine 
(2t). 
To a solution of homoallylamine 1 (1.3 g, 5.0 mmol) in toluene (50 mL) at room 
temperature was added NaHCO3 (2.1 g, 25.0 mmol) and iodine (5,07 g, 20.0 mmol) 
and the obtained dark brown mixture was stirred for 24 h at the same temperature. 
Then saturated aqueous Na2SO3 (40 mL) was added and the mixture was stirred for 
15 min. The organic layer was separated and the aqueous layer was extracted with 
EtOAc (2 × 40 mL). The combined organic extracts were dried over anhydrous 
MgSO4, filtered and concentrated in vacuo. The resulting crude was dissolved in 
MeCN (120 mL). After stirring for 4 h at 40 ºC the solvent was removed in vacuo. 
Purification of the residue by silica gel column chromatography (first eluent: 
Et2O/hexanes, 1:7; second eluent Et2O/hexanes, 1:4) yielded 1.2 g (62% yield) of a 
60/40 mixture of 2c and 2t as a pale yellow oil that was used in the next step without 
additional purification. In order to characterise both diastereoisomers a small amount 
of the mixture was purified again by silica gel column chromatography (eluent: 
Et2O/hexanes, 1:15). NMR data for (2S,4S)-1-benzyl-2-[(S)-2,2-dimethyl-1,3-
dioxolan-4-yl]-4-iodopyrrolidine (major compound 2c): 1H NMR (400 MHz, CDCl3): δ 
= 1.36 (s, 3H), 1.41 (s, 3H), 2.17 (ddd, J = 14.4, 7.2, 7.2 Hz, 1H), 2.71 (ddd, J = 14.4, 
7.4, 7.4 Hz, 1H), 2.91 (dd, J = 11.6, 6.2 Hz, 1H), 3.04 (ddd, J = 7.4, 7.4, 6.0 Hz, 1H), 
3.17 (dd, J = 11.6, 6.8 Hz, 1H), 3.58 (d, J = 13.6, 1H), 3.84 (dd, J =8.0, 7.2 Hz, 1H), 
4.03–4.08 (m, 2H), 4.12–4.19 (m, 1H), 4.23 (ddd, J =6.8, 6.0, 6.0 Hz, 1H), 7.23–7.34 
(m, 5H); 13C NMR (100 MHz, CDCl3): δ = 17.5, 25.4, 26.8, 41.8, 60.0, 64.9, 65.3, 
67.2, 78.6, 109.1, 127.3, 128.5, 128.6, 139.3. NMR data for (2S,4R)-1-benzyl-2-[(S)-
2,2-dimethyl-1,3-dioxolan-4-yl]-4-iodopyrrolidine (minor compound 2t): 1H NMR (400 
MHz, CDCl3): δ = 1.34 (s, 3H), 1.42 (s, 3H), 2.27–2.46 (m, 2H), 2.82 (dd, J = 10.0, 
8.8 Hz, 1H), 3.06-3.10 (m, 1H), 3.42 (dd, J =10.0, 6.0 Hz, 1H), 3.66–3.71 (m, 2H), 
4.00 (dd, J = 7.8, 6.6 Hz, 1H), 4.09–4.19 (m, 3H), 7.23–7.34 (m, 5H); 13C NMR (100 
MHz, CDCl3): δ = 16.7, 25.3, 26.6, 40.5, 59.8, 64.5, 65.5, 66.9, 77.4, 109.2, 127.3, 
128.5, 128.9, 138.9. 
(2S,4S)-4-Azido-1-benzyl-2-[(S)-2,2-dimethyl-1,3-dioxolan-4-yl]pyrrolidine (3c) 
and (2S,4R)-4-azido-1-benzyl-2-[(S)-2,2-dimethyl-1,3-dioxolan-4-yl]pyrrolidine 
(3t). 
A solution of a 60/40 mixture of iodopyrrolidines 2c and 2t (863 mg, 2.16 mmol), 
sodium azide (562 mg, 8.64 mmol) in dry DMF (16 mL) was stirred at 70ºC for 4h. 
Then solvent was removed in vacuo and the residue was diluted with water and 
extracted with CH2Cl2 (3 × 30 mL). The combined organic extracts were dried over 
anhydrous MgSO4, filtered and concentrated in vacuo. Purification of the residue by 
silica gel column chromatography (eluent: Et2O/hexanes, 1:4) yielded 613 mg (94% 
yield) an inseparable 60/40 mixture of 3t and 3c as a colourless oil that was used in 
the next step without additional purification. In order to characterise both 
diastereoisomers the same synthetic procedure was applied to samples of 2c and 2t 
isolated in the previous step. NMR data for (2S,4R)-4-azido-1-benzyl-2-[(S)-2,2-
dimethyl-1,3-dioxolan-4-yl]pyrrolidine (major compound 3t): 1H NMR (400 MHz, 
CDCl3): δ = 1.28 (s, 3H), 1.37 (s, 3H), 1.88 (ddd, J = 13.6, 8.4, 5.6 Hz, 1H), 2.01–
2.08 (m, 1H), 2.35 (dd, J = 10.0, 6.4 Hz, 1H), 2.99 (ddd, J = 8.6, 6.2, 3.6 Hz, 1H), 
3.12 (dd, J = 10.0, 6.0 Hz, 1H), 3.52 (d, J = 13.2 Hz, 1H), 3.62 (dd, J = 7.6, 7.6 Hz, 
1H), 3.90–3.96 (m, 2H), 3.99 (d, J = 13.2 Hz, 1H), 4.07–4.11 (m, 1H), 7.16–7.29 (m, 
5H); 13C NMR (100 MHz, CDCl3): δ = 25.1, 26.4, 33.2, 58.9, 59.2, 59.6, 63.4, 66.8, 
77.1, 109.1, 127.2, 128.4, 128.8, 138.8. (2S,4S)-4-azido-1-benzyl-2-[(S)-2,2-
dimethyl-1,3-dioxolan-4-yl]pyrrolidine (minor compound 3c): 1H NMR (400 MHz, 
CDCl3): δ = 1.30 (s, 3H), 1.36 (s, 3H), 1.81 (dddd, J = 14.2, 6.0, 2.8, 1.4 Hz, 1H), 
2.24 (ddd, J = 14.2, 9.2, 7.6 Hz, 1H), 2.42 (dd, J =10.8, 5.2 Hz, 1H), 2.83 (ddd, J = 
9.4, 6.0, 4.8 Hz, 1H), 2.92 (ddd, J =10.8, 1.6, 1.6 Hz, 1H), 3.33 (d, J = 13.4 Hz, 1H), 
3.79–3.84 (m, 2H), 4.01 (dd, J = 8.0, 6.4 Hz, 1H), 4.11 (d, J =13.4 Hz, 1H), 4.19 (ddd, 
J = 7.6, 6.4, 4.8 Hz, 1H), 7.16–7.28 (m, 5H); 13C NMR (100 MHz, CDCl3): δ = 25.3, 
26.6, 34.1, 58.9, 59.4, 59.4, 63.4, 66.8, 77.9, 109.0, 127.2, 128.4, 128.7, 138.7. 
(2S,4S)-4-Amino-1-benzyl-2-[(S)-2,2-dimethyl-1,3-dioxolan-4-yl]pyrrolidine (4c) 
and (2S,4R)-4-amino-1-benzyl-2-[(S)-2,2-dimethyl-1,3-dioxolan-4-yl]pyrrolidine 
(4t). 
A suspension of a 60/40 mixture of azidopyrrolidines 3t and 3c (613 mg, 2.03 mmol) 
in EtOH (16 mL) was hydrogenated with molecular hydrogen for 2 h at atmospheric 
pressure and room temperature in the presence of 10% Pd/C (61.3 mg) as a catalyst. 
The catalyst was removed by filtration through a Celite® pad and the solvent 
evaporated in vacuo. CH2Cl2 (30 mL) and 1M aqueous NaOH (15 mL) were added 
and the biphasic solution was stirred for 10 min at room temperature. The aqueous 
layer was separated and extracted with CH2Cl2 (2 × 30 mL). The combined organic 
extracts were dried over anhydrous MgSO4, filtered and concentrated in vacuo to 
afford 480 mg (86% yield) of a 60/40 mixture of 4t and 4c as a pale yellow oil which 
was used in the next step without additional purification. NMR data obtained from the 
diastereomeric mixture for (2S,4R)-4-amino-1-benzyl-2-[(S)-2,2-dimethyl-1,3-
dioxolan-4-yl]pyrrolidine (major compound 4t): 1H NMR (400 MHz, CDCl3): δ = 1.31 
(s, 3H), 1.39 (s, 3H), 1.52–1.60 (m, 1H), 1.85–1.98 (m, 2H), 2.00–2.07 (m, 2H), 2.96–
3.00 (m, 1H), 3.08–3.12 (m, 1H), 3.38–3.49 (m, 2H), 3.63–3.72 (m, 1H), 3.95–4.06 
(m, 2H), 4.09–4.13 (m, 1H), 7.18–7.31 (m, 5H); 13C NMR (100 MHz, CDCl3): δ = 25.1, 
26.4, 36.8, 49.7, 59.9, 63.2, 63.4, 66.5, 77.5, 108.8, 126.9, 128.1, 128.8, 139.0. NMR 
data obtained from the diastereomeric mixture for (2S,4S)-4-amino-1-benzyl-2-[(S)-
2,2-dimethyl-1,3-dioxolan-4-yl]pyrrolidine (minor compound 4c): 1H NMR (400 MHz, 
CDCl3): δ = 1.32 (s, 3H), 1.42 (s, 3H), 1.52–1.60 (m, 1H), 1.85–1.98 (m, 2H), 2.18 
(ddd, J = 14.0,10.0, 7.2 Hz, 1H), 2.42 (dd, J = 10.0, 4.8, Hz 1H), 2.66–2.70 (m, 1H), 
2.73–2.78 (m, 1H), 3.26–3.35 (m, 1H), 3.38–3.49 (m, 1H), 3.63–3.72 (m, 1H), 3.95–
4.06 (m, 2H), 4.23 (ddd, J = 7.2, 7.2, 2.4 Hz, 1H), 7.18–7.31 (m, 5H); 13C NMR (100 
MHz, CDCl3): δ = 25.0, 26.3, 35.9, 49.6, 58.7, 63.2, 63.4, 66.7, 76.4, 108.9, 126.8, 
128.1, 128.7, 139.0. 
 
N-{(2R,4S)-1-Benzyl-2-[(S)-2,2-dimethyl-1,3-dioxolan-4-yl]-4-
[(trifluoromethyl)sulfonamido]pyrrolidine (5t) and N-{(2S,4S)-1-benzyl-5-[(S)-
2,2-dimethyl-1,3-dioxolan-4-yl]-4-[(trifluoromethyl)sulfonamido]pyrrolidine (5c). 
Trifluoromethanesulfonic anhydride (277 mL, 1.65 mmol) was added dropwise to a 
solution of a 60/40 mixture of 4-aminopyrrolidines 4t and 4c (456 mg, 1.65 mmol) 
and Et3N (276 mL, 1.98 mmol) in CH2Cl2 (3.5 mL) at 0 ºC. After stirring for 1h at 0º C 
the solution was allowed to warm up to room temperature and stirring was continued 
for 16 h while monitoring by TLC to add Et3N if necessary. Then reaction mixture was 
concentrated in vacuo and the residue purified by silica gel column chromatography 
(first eluent: Et2O/hexanes, 1:2; second eluent Et2O/hexanes, 1:1) to afford 312 mg 
(46% yield) of diastereomerically pure 5t and 206 mg (31% yield) of 
diastereomerically pure 5c, 76% overall yield. Data for N-{(2R,4S)-1-benzyl-2-[(S)-
2,2-dimethyl-1,3-dioxolan-4-yl]-4-[(trifluoromethyl)sulfonamido]pyrrolidine (5t): White 
solid; mp: 96.6 – 98.5 ºC; [α]25D = –30.2 (c = 1.00, CHCl3); IR (KBr): ν = 1498, 1459, 
1353, 1185 cm–1; 1H NMR (400 MHz, CDCl3): δ = 1.27 (s, 3H), 1.36 (s, 3H), 1.72 
(ddd, J = 13.2, 9.2, 7.6 Hz, 1H), 2.19-2.28 (m, 2H), 2.96 (ddd, J = 8.0, 4.4, 3.2 Hz, 
1H), 3.19 (dd, J = 9.2, 6.0 Hz, 1H), 3.52–3.58 (m, 2H), 3.89–3.93 (m, 2H), 4.03–4.12 
(m, 2H), 4.40 (bs, 1H), 7.12–7.27 (m, 5H); 13C NMR (100 MHz, CDCl3): δ = 25.0, 
26.3, 34.1, 53.2, 58.2, 59.6, 62.2, 66.6, 76.4, 109.5, 119.6 (q, J = 320 Hz), 127.6, 
128.6, 128.9, 137.9); 19F NMR (376 MHz, CDCl3): δ = –77.55; HRMS (ESI+): calcd. 
for C17H24F3N2O4S [MH]+ 409.1403; found 409.1420. Data for N-{(2S,4S)-1-benzyl-5-
[(S)-2,2-dimethyl-1,3-dioxolan-4-yl]-4-[(trifluoromethyl)sulfonamido]pyrrolidine (5c): 
Colourless oil; [α]25D = –57.6 (c = 1.00, CHCl3); IR (KBr): ν = 3224, 1378, 1193, 1153 
cm–1; 1H NMR (400 MHz, CDCl3): δ = 1.28 (s, 3H), 1.44 (s, 3H), 1.83 (ddd, J = 14.0, 
2.4, 2.4 Hz, 1H), 2.10–2.20 (m, 1H), 2.44 (dd, J = 9.8, 3.4 Hz, 1H), 2.80 (ddd, J = 
10.6, 2.4, 1.4 Hz, 1H), 2.88 (dd, J = 9.8, 2.2 Hz, 1H), 3.37 (dd, J = 8.0, 7.6 Hz, 1H) , 
3.51 (d, J = 13.6 Hz, 1H), 3.90–3.95 (m, 3H), 4.18 (ddd, J = 7.4, 7.4, 1.2 Hz, 1H), 
7.17–7.28 (m, 5H); 13C NMR (100 MHz, CDCl3): δ = 24.7, 25.9, 32.4, 53.9, 57.5, 
60.4, 62.2, 66.9, 75.0, 110.0, 119.8 (q, J = 320 Hz), 127.5, 128.5, 128.6, 138.2; 19F 
NMR (376 MHz, CDCl3): δ = –77.99; HRMS (ESI+): calcd. for C17H23F3N2O4SNa 
[MNa]+ 431.1223; found 431.1250. 
 
N-{(2R,4S)-1-Benzyl-2-[(S)-2,2-dimethyl-1,3-dioxolan-4-yl]-4-[(4-
methylphenyl)sulfonamido]pyrrolidine (6t) and N-{(2S,4S)-1-benzyl-5-[(S)-2,2-
dimethyl-1,3-dioxolan-4-yl]-4-[(4-methylphenyl)sulfonamido]pyrrolidine (6c). 
p-Toluensulfonyl chloride (425 mg, 2.23 mmol) was added dropwise to a solution of a 
60/40 trans/cis mixture of compound 4 (410 mg, 1.48 mmol) and Et3N (414 mL, 2.97 
mmol) in CH2Cl2 (3 mL) at 0 ºC. After stirring for 1h at 0º C the solution was allowed 
to warm up to room temperature and stirring was continued for 12 h. Then reaction 
mixture was concentrated in vacuo and the residue purified by silica gel column 
chromatography (first eluent: Et2O/hexanes, 1:1; second eluent Et2O/hexanes, 2:1) to 
afford 345 mg (54% yield) of diastereomerically pure 6t and 231 mg (36% yield) of 
diastereomerically pure 6c, 90% overall yield. Data for N-{(2R,4S)-1-benzyl-2-[(S)-
2,2-dimethyl-1,3-dioxolan-4-yl]-4-[(4-methylphenyl)sulfonamido]pyrrolidine (6t): White 
solid; mp: 87.9 – 89.3 ºC; [α]25D = –10.7 (c = 1.00, CHCl3); IR (KBr): ν = 3304, 1329, 
1160, 1090 cm–1; 1H NMR (400 MHz, CDCl3): δ = 1.31 (s, 3H), 1.36 (s, 3H), 1.69 
(ddd, J =13.2, 9.2, 7.6 Hz, 1H), 1.99–2.06 (m, 1H), 2.17 (dd, J =8.8, 8.8 Hz, 1H), 2.42 
(s, 3H), 2.89–2.94 (m, 1H), 3.02 (dd, J = 9.2, 6.4 Hz, 1H), 3.49 (d, J =13.2 Hz, 1H), 
3.57 (dd, J = 7.6, 7.6 Hz, 1H), 3.67–6.76 (m, 1H), 3.91–3.96 (m, 2H), 4.07 (ddd, J 
=6.8, 6.8, 3.2 Hz, 1H), 5.24 (bs, 1H), 7.22–7.30 (m, 7H), 7.73–7.76 (m, 2H); 13C NMR 
(100 MHz, CDCl3): δ = 21.6, 25.1, 26.3, 33.6, 51.3, 59.1, 59.8, 62.5, 66.5, 76.7, 
109.2, 127.2, 128.3, 129.0, 129.8, 137.3, 138.3, 143.6; HRMS (ESI+): calcd. for 
C23H31N2O4S [MH]+ 431.1999; found 431.2006. Data for N-{(2S,4S)-1-benzyl-5-[(S)-
2,2-dimethyl-1,3-dioxolan-4-yl]-4-[(4-methylphenyl)sulfonamido]pyrrolidine (6c): 
White solid; mp: 118.8 – 121.0 ºC; [α]25D = –86.6 (c = 1.00, CHCl3); IR (KBr): ν = 
3318, 1328, 1156, 1097 cm–1; 1H NMR (400 MHz, CDCl3): δ = 1.38 (s, 3H), 1.54 (s, 
3H), 1.76–1.81 (m, 1H), 2.12 (ddd, J = 13.8, 10.4, 7.0 Hz, 1H), 2.22 (dd, J = 9.6, 3.6 
Hz, 1H), 2.37 (s, 3H), 2.51–2.55 (m, 1H), 2.73–2.77 (m, 1H), 3.40 (d, J = 13.6 Hz, 
1H), 3.47 (dd, J = 7.6, 7.6 Hz, 1H), 3.78–3.83 (m, 1H), 3.94–4.02 (m, 2H), 4.25 (ddd, 
J = 7.2, 7.2, 1.6 Hz, 1H), 5.95 (d, J = 9.6 Hz, 1H), 7.15–7.18 (m, 2H), 7.22–7.33 (m, 
5H), 7.66–7.69 (m, 2H); 13C NMR (100 MHz, CDCl3): δ = 21.5, 24.9, 26.3, 32.8, 51.9, 
57.9, 59.3, 62.7, 66.9, 75.2, 109.7, 126.9, 127.2, 128.4, 128.7, 129.6, 138.6, 138.7, 
142.9; HRMS (ESI+): calcd. for C23H31N2O4S [MH]+ 431.1999; found 431.2003. 
 
N-{(3R,5S)-5-[(S)-2,2-Dimethyl-1,3-dioxolan-4-yl]pyrrolidin-3-yl}-1,1,1-
trifluoromethanesulfonamide OC1. 
A suspension of pyrrolidine 5t (294 mg, 0.72 mmol) in EtOH (6 mL) was 
hydrogenated with molecular hydrogen for 12 h at atmospheric pressure and room 
temperature in the presence of 10% Pd/C (102.9 mg) as a catalyst. The catalyst was 
removed by filtration through a Celite® pad and the solvent evaporated in vacuo. 
Purification of the residue by silica gel column chromatography (first eluent: 
Et2O/hexanes, 1:1; second eluent EtOAc/EtOH, 7:1) yielded 190 mg (83% yield) of 
organocatalyst OC1. Brownish solid; mp: 178.8 – 181.0 ºC; [α]25D = +1.88 (c = 1.00, 
MeOH); IR (KBr): ν = 3568, 3497, 3100-2400, 1270, 1202 cm–1; 1H NMR (400 MHz, 
acetone-d6): δ = 1.28 (s, 3H), 1.36 (s, 3H), 2.00–2.15 (m, 2H), 3.05 (ddd, J = 11.4, 
3.4, 1.0 Hz, 1H), 3.32 (dd, J = 11.4, 5.6 Hz, 1H), 3.66 (ddd, J =7.6, 7.6, 6.4 Hz, 1H) , 
3.77 (dd, J = 8.4, 6.0 Hz, 1H), 4.08 (dd, J = 8.4, 6.4 Hz, 1H), 4.14–4.20 (m, 1H), 4.23 
(ddd, J = 6.0, 6.0, 6.0 Hz, 1H); 13C NMR (100 MHz, acetone-d6): δ = 25.3, 26.9, 36.7, 
54.7, 56.4, 60.3, 67.9, 77.8, 110.0, 121.9 (q, J = 320 Hz); 19F NMR (376 MHz, 
acetone-d6): δ = –80.00; HRMS (ESI+): calcd. for C10H18F3N2O4S [MH]+ 319.0934; 
found 319.0927. 
 
N-{(3S,5S)-5-[(S)-2,2-Dimethyl-1,3-dioxolan-4-yl]pyrrolidin-3-yl}-1,1,1-
trifluoromethanesulfonamide OC2. 
A suspension of pyrrolidine 5c (206 mg, 0.50 mmol) in EtOH (4 mL) was 
hydrogenated with molecular hydrogen for 12 h at atmospheric pressure and room 
temperature in the presence of 10% Pd/C (72.9 mg) as a catalyst. The catalyst was 
removed by filtration through a Celite® pad and the solvent evaporated in vacuo. 
Purification of the residue by silica gel column chromatography (first eluent: 
Et2O/hexanes, 1:1; second eluent EtOAc/EtOH, 7:1) yielded 129 mg (81% yield) of 
organocatalyst OC2. Brownish solid; mp: 187.2 – 187.9 ºC; [α]25D = –3.8 (c = 1.00, 
MeOH); IR (KBr): ν = 3500-2500, 1255, 1189, 1166 cm–1; 1H NMR (400 MHz, 
acetone-d6): δ = 1.27 (s, 3H), 1.34 (s, 3H), 1.71 (ddd, J = 13.6, 7.2, 7.2 Hz, 1H), 2.40 
(ddd, J = 13.6, 8.0, 8.0 Hz, 1H), 2.84 (dd, J = 11.2, 6.0 Hz, 1H), 3.19 (dd, J = 11.2, 
6.8 Hz, 1H), 3.23–3.28 (m, 1H), 3.69–3.76 (m, 1H), 4.01–4.11 (m, 3H); 13C NMR (100 
MHz, acetone-d6): δ = 25.6, 27.0, 36.7, 53.7, 56.4, 60.2, 68.2, 79.7, 109.6, 121.0 (q, J 
= 320 Hz); 19F NMR (376 MHz, acetone-d6): δ = –80.07; HRMS (ESI+): calcd. for 
C10H18F3N2O4S [MH]+ 319.0934; found 319.0950. 
 
N-{(3R,5S)-5-[(S)-2,2-Dimethyl-1,3-dioxolan-4-yl]pyrrolidin-3-yl)} 4-
methylbenzenesulfonamide OC3. 
A suspension of pyrrolidine 6t (301 mg, 0.70 mmol) in EtOH (5.6 mL) was 
hydrogenated with molecular hydrogen for 12 h at atmospheric pressure and room 
temperature in the presence of 10% Pd/C (105.9 mg) as a catalyst. The catalyst was 
removed by filtration through a Celite® pad and the solvent evaporated in vacuo. 
Purification of the residue by silica gel column chromatography (eluent: EtOAc/EtOH, 
5:1) yielded 219 mg (92% yield) of organocatalyst OC3. Brownish solid; mp: 99.8 – 
101.3 ºC; [α]25D = +6.4 (c = 1.00, CHCl3); IR (KBr): ν = 3561, 3317, 3101, 1327, 
1163, 1057 cm–1; 1H NMR (400 MHz, acetone-d6): δ = 1.22 (s, 3H), 1.27 (s, 3H), 
1.69–1.82 (m, 2H), 2.42 (s, 3H), 2.68 (dd, J = 11.2, 4.6 Hz, 1H), 2.88 (dd, J = 11.2, 
5.6 Hz, 1H), 3.20 (ddd, J = 7.2, 7.2, 7.2 Hz, 1H), 3.64 (dd, J = 8.0, 6.0 Hz, 1H), 3.66–
3.71 (m, 1H), 3.81 (ddd, J = 7.2, 6.4 Hz, 6.4 Hz, 1H), 3.95 (dd, J = 8.0, 6.4 Hz, 1H), 
7.38–7.41 (m, 2H), 7.74–7.77 (m, 2H); 13C NMR (100 MHz, acetone-d6): δ = 21.4, 
25.6, 27.1, 36.5, 53.8, 55.3, 60.1, 68.3, 80.0, 109.4, 127.8, 130.4, 139.7, 143.8; 
HRMS (ESI+): calcd. for C16H25N2O4S [MH]+ 341.1530; found 341.1538. 
 
N-{(3S,5S)-5-[(S)-2,2-Dimethyl-1,3-dioxolan-4-yl]pyrrolidin-3-yl)} 4-
methylbenzenesulfonamide OC4. 
A suspension of pyrrolidine 6c (168 mg, 0.39 mmol) in EtOH (3 mL) was 
hydrogenated with molecular hydrogen for 12 h at atmospheric pressure and room 
temperature in the presence of 10% Pd/C (59.0 mg) as a catalyst. The catalyst was 
removed by filtration through a Celite® pad and the solvent evaporated in vacuo. 
Purification of the residue by silica gel column chromatography (eluent: EtOAc/EtOH, 
5:1) yielded 122 mg (92% yield) of organocatalyst OC4. Brownish solid; mp: 122.5 – 
123.9 ºC; [α]25D = –10.1 (c = 1.00, CHCl3); IR (KBr): ν = 3337, 3100-2500, 1302, 
1150, 1074 cm–1; 1H NMR (400 MHz, acetone-d6): δ = 1.24 (s, 3H), 1.29 (s, 3H), 1.46 
(ddd, J = 13.2, 7.6, 7.6 Hz, 1H), 2.10 (ddd, J = 13.2, 7.6, 7.6 Hz, 1H), 2.42 (s, 3H), 
2.55 (dd, J = 11.2, 6.0 Hz, 1H), 2.89 (dd, J = 11.2, 6.8 Hz, 1H) , 3.06 (ddd, J = 7.6, 
7.6, 7.6 Hz, 1H), 3.63-3.70 (m, 2H), 3.91 (ddd, J = 6.4, 6.4 Hz, 6.4 Hz, 1H), 3.96 (dd, 
J = 7.6, 6.4 Hz, 1H), 7.38-7.41 (m, 2H), 7.74-7.77 (m, 2H); 13C NMR (100 MHz, 
acetone-d6): δ = 21.4, 25.6, 27.1, 36.7, 53.3, 55.3, 60.2, 68.3, 80.2, 109.4, 127.8, 
130.4, 139.8, 143.8; HRMS (ESI+): calcd. for C16H25N2O4S [MH]+ 341.1530; found 
341.1519. 
 
General procedure for the Michael reaction of aldehydes with β-nitroolefins.  
A solution of the corresponding organocatalyst OC1–OC4 (0.02 mmol), and aldehyde 
(0.4 mmol) in the selected solvent (2 mL) was stirred at the specified temperature for 
10 min. The nitroolefin (0.2 mmol) was added and stirring was continued for the 
required time at the same temperature. The reaction was concentrated in vacuo and 
the residue was analysed by 1H NMR using 1,3,5-trimethoxybenzene as internal 
standard16 to determine the reaction yield and diastereoselectivity. Purification of the 
residue by silica gel column chromatography yielded the corresponding Michael 
adducts. Enantioselectivity was determined by chiral HPLC analysis of the purified 
adducts using a chiral stationary phase. 
 
 
(R)-2-[(S)-2-Nitro-1-phenylethyl]pentanal (9a). 
Obtained in nearly quantitative yield with a dr 94/6 and 93% ee (entry 1, table 2). 
Eluent for residue purification Et2O/hexanes 1:3. Chromatographic and spectroscopic 
data are in accordance with those previously reported.17 Chiral HPLC analysis: 
Chiralcel® OD-H column, hexane/iPrOH 95:5, flow rate 1.0 mL min–1, λ = 220 nm, tR = 
25.8 min (minor) and 32.4 min (major). 1H NMR (400 MHz, CDCl3): δ = 0.79 (t, J = 
7.2 Hz, 3H), 1.10–1.22 (m, 1H), 1.24–1.39 (m, 2H), 1.41–1.52 (m, 1H), 2.70 (dddd, J 
= 9.2, 9.2, 3.2, 3.2 Hz, 1H), 3.77 (ddd, J = 9.6, 9.6, 5.2 Hz, 1H), 4.64 (dd, J =12.6, 9.4 
Hz, 1H), 4.70 (dd, J =12.6, 5.2 Hz, 1H), 7.15–7.18 (m, 2H), 7.25–7.36 (m, 3H), 9.69 
(d, J = 2.8 Hz, 1H). 13C NMR (100 MHz, CDCl3): δ = 14.0, 19.9, 29.6, 43.2, 53.9, 
78.5, 128.1, 128.2, 129.2, 136.9, 203.4. 
 
(2R,3S)-2-Benzyl-4-nitro-3-phenylbutanal (9b).  
Obtained in 94% yield with a dr 95/5 and 88% ee (entry 2, table 2). Eluent for residue 
purification Et2O/hexanes 1:3. Chromatographic and spectroscopic data are in 
accordance with those previously reported.18 Chiral HPLC analysis: Chiralcel® OD-H 
column, hexane/EtOH 93:7, flow rate 1.0 mL min–1, λ = 220 nm, tR = 29.0 min (minor) 
and 33.1 min (major). 1H NMR (400 MHz, CDCl3): δ = 2.74–2.84 (m, 2H), 3.14 (dddd; 
J = 8.8, 8.8, 5.9, 2.4 Hz, 1H), 3.86 (ddd, J = 8.8, 8.8, 6.0 Hz, 1H), 4.72 (dd, J = 12.8, 
8.8 Hz, 1H), 4.76 (dd, J = 12.8, 6.0 Hz, 1H), 7.04–7.07 (m, 2H), 7.23–7.37 (m, 6H), 
7.37–7.43 (m, 2H), 9.73 (d, J = 2.2 Hz, 1H). 13C NMR (100 MHz, CDCl3): δ = 34.3, 
43.6, 55.4, 78.1, 127.1, 128.2, 128.4, 128.9, 128.9, 129.4, 136.8, 137.3, 203.1. 
 
(2R,3S)-2-Ethyl-4-nitro-3-phenylbutanal (9c). 
Obtained in nearly quantitative yield with a dr 91/9 and 91% ee (entry 3, table 2). 
Eluent for residue purification Et2O/hexanes 1:4. Chromatographic and spectroscopic 
data are in accordance with those previously reported.19 Chiral HPLC analysis: 
Chiralpak® IC column, hexane/iPrOH 90:10, flow rate 1.0 mL min–1, λ = 220 nm, tR = 
36.5 min (minor) and 40.3 min (major). 1H NMR (400 MHz, CDCl3): δ = 0.83 (t, J= 7.4 
Hz, 3H), 1.47–1.55 (m, 2H), 2.65–2.71 (m, 1H), 3.79 (ddd, J = 9.8, 9.8, 5.0 Hz, 1H), 
4.63 (dd, J = 12.8, 9.8 Hz, 1H), 4.72 (dd, J = 12.8, 4.8 Hz, 1H) , 7.16–7.19 (m, 2H), 
7.27–7.37 (m, 3H), 9.72 (d, J = 2.8 Hz, 1H). 13C NMR (100 MHz, CDCl3): δ = 10.8, 
20.5, 42.8, 55.1, 78.7, 128.1, 128.3, 129.2, 136.9, 203.3. 
 
(2R,3S)-2-Methyl-4-nitro-3-phenylbutanal (9d). 
Obtained in nearly quantitative yield with a dr 95/5 and 91% ee (entry 4, table 2). 
Eluent for residue purification Et2O/hexanes 1:2. Chromatographic and spectroscopic 
data are in accordance with those previously reported.20 Chiral HPLC analysis: 
Chiralcel® OD-H column, hexane/iPrOH 80:20, flow rate 1.0 mL min–1, λ = 220 nm, tR 
= 18.2 min (minor) and 24.7 min (major). 1H NMR (400 MHz, CDCl3): δ = 0.99 (d, J = 
7.2 Hz, 3H), 2.72–2.83 (m, 1H), 3.81 (ddd, J = 9.2, 9.2, 5.6 Hz, 1H), 4.68 (dd, J = 
12.4, 9.2 Hz, 1H), 4.80 (dd, J = 12.4, 5.6 Hz, 1H), 7.14–7.18 (m, 2H), 7.26–7.35 (m, 
3H), 9.70 (d, J = 2.0 Hz, 1H). 13C NMR (100 MHz, CDCl3): δ = 12.2, 44.1, 48.5, 78.2, 
128.2, 128.2, 129.2, 136.7, 202.4. 
 
(R)-2-[(S)-2-Nitro-1-phenylethyl]octanal (9e). 
Obtained in nearly quantitative yield with a dr 93/7, and 93% ee (entry 5, table 2). 
Eluent for residue purification Et2O/hexanes 1:5. Chromatographic and spectroscopic 
data are in accordance with those previously reported.21 Chiral HPLC analysis: 
Chiralcel® OD-H column, hexane/iPrOH 90:10, flow rate 0.5 mL min–1, λ = 220 nm, tR 
= 31.4 min (minor) and 38.4 min (major). 1H NMR (400 MHz, CDCl3): δ = 0.82 (t, J = 
7.2 Hz, 3H), 1.11–1.51 (m, 10H), 2.70 (dddd; J = 9.2, 9.2, 4.0, 2.8 Hz, 1H), 3.77 (ddd, 
J = 9.6, 9.6, 5.2 Hz, 1H), 4.64 (dd, J = 12.8, 9.6 Hz, 1H), 4.71 (dd, J = 12.8, 5.2 Hz, 
1H), 7.16–7.19 (m, 2H), 7.26–7.38 (m, 3H), 9.70 (d, J = 2.8 Hz, 1H). 13C NMR (100 
MHz, CDCl3): δ = 14.1, 22.5, 26.5, 27.5, 29.2, 31.5, 43.3, 54.0, 78.6, 128.1, 128.3, 
129.2, 136.9, 203.4. 
 
(R)-2-[(S)-2-Nitro-1-phenylethyl]undec-10-enal (9f). 
Obtained in nearly quantitative yield with a dr 97/3, and 92% ee (entry 6, table 2). 
Eluents for residue purification Et2O/hexanes 1:8 and after Et2O/hexanes 1:4. 
Chromatographic and spectroscopic data are in accordance with those previously 
reported.19 Chiral HPLC analysis: Chiralpak® IC column, hexane/iPrOH 90:10, flow 
rate 1.0 mL min–1, λ = 220 nm, tR = 22.7 min (minor) and 25.1 min (major). 1H NMR 
(400 MHz, CDCl3): δ = 1.11–1.52 (m, 12H), 1.96–2.02 (m, 2H), 2.69 (dddd, J = 9.4, 
9.4, 3.8, 2.8 Hz,1H), 3.77 (ddd, J = 9.6, 9.6, 5.2 Hz, 1H), 4.63 (dd, J = 12.8, 9.4 Hz, 
1H), 4.70 (dd, J = 12.8, 5.2 Hz, 1H), 4.92 (dddd, J = 10.2, 2.4, 1.2, 1.2 Hz, 1H), 4.97 
(dddd, J = 17.0, 2.4, 1.8, 1.8 Hz, 1H), 4.78 (dddd, J = 17.0, 10.2, 6.8, 6.8 Hz, 1H), 
7.15–7.18 (m, 2H) , 7.27–7.36 (m, 3H), 9.70 (d, J = 2.4, 1H). 13C NMR (100 MHz, 
CDCl3): δ = 26.4, 27.4, 28.9, 28.9, 29.1, 29.4, 33.8, 43.2, 54.0, 78.6, 114.3, 128.1, 
128.3, 129.2, 136.9, 139.2, 203.3. 
 
(2R,3S)-2-isopropyl-4-nitro-3-phenylbutanal (9g). 
Obtained in nearly quantitative yield with a dr 98/2, and 97% ee (entry 7, table 2). 
Eluent for residue purification Et2O/hexanes 1:4. Chromatographic and spectroscopic 
data are in accordance with those previously reported.22 Chiral HPLC analysis: 
Chiralpak® IA column, hexane/iPrOH 98:2, flow rate 0.5 mL min–1, λ = 220 nm, tR = 
31.3 min (major) and 40.3 min (minor). 1H NMR (400 MHz, CDCl3): δ = 0.81 (d. J = 
6.8 Hz. 3H). 1.03 (d. J = 7. 2 Hz. 3H). 1.59–1.70 (m. 1H), 2.70 (ddd, J = 10.8, 4.0, 2.4 
Hz, 1H), 3.83 (ddd, = 10.4, 10.4, 4.4 Hz, 1H), 4.50 (dd, J = 12.4, 10.0 Hz, 1H), 4.60 
(dd, J = 12.4, 4.4 Hz, 1H), 7.10–7.13 (m, 2H), 7.19–7.30 (m, 3H), 9.86 (d, J = 2.4 Hz, 
1H). 13C NMR (100 MHz, CDCl3): δ = 17.1, 21.8, 28.0, 42.1, 58.9, 79.1, 128.1, 128.2, 
129.3, 137.2, 204.5. 
 
(R)-2-[(R)-1-(Furan-2-yl)-2-nitroethyl]pentanal (9h). 
Obtained in 98% yield with a dr 89/11 and 75% ee (entry 8, table 2). Eluent for 
residue purification Et2O/hexanes 1:5. Chromatographic and spectroscopic data are 
in accordance with those previously reported.20 Chiral HPLC analysis: Chiralcel® OD-
H column, hexane/iPrOH 95:5, flow rate 0.8 mL min–1, λ = 220 nm, tR = 17.3 min 
(major) and 18.5 min (minor). 1H NMR (400 MHz, CDCl3): δ = 0.88 (t, J = 7.2 Hz, 3H), 
1.20–1.57 (m, 4H), 2.78 (dddd, J = 8.2, 8.2, 4.0, 2.0 Hz, 1H), 4.00 (ddd, J = 9.0, 8.2, 
5.2 Hz, 1H), 4.65 (dd, J = 12.8, 5.2 Hz, 1H), 4.72 (dd, J = 12.8, 9.2 Hz, 1H), 6.19 (dd, 
J = 3.2, 0.8 Hz, 1H), 6.31 (dd, J = 3.2, 1.8 Hz, 1H), 7.37 (dd, J = 1.8, 0.8 Hz, 1H), 
9.71 (d, J = 2.0 Hz, 1H). 13C NMR (100 MHz, CDCl3): δ = 14.2, 20.1, 29.2, 37.1, 52.3, 
76.2, 108.9, 110.6, 142.8, 150.2, 202.5. 
 
(R)-2-[(S)-1-(4-Methoxyphenyl)-2-nitroethyl]pentanal (9i). 
Obtained in nearly quantitative yield with a dr 83/7 and 89% ee (entry 9, table 2). 
Eluent for residue purification Et2O/hexanes 1:5. Chromatographic and spectroscopic 
data are in accordance with those previously reported.23 Chiral HPLC analysis: 
Chiralpak® IC column, hexane/iPrOH 80:20, flow rate 0.8 mL min–1, λ = 220 nm, tR = 
27.6 min (minor) and 30.6 min (major). 1H NMR (400 MHz, CDCl3): δ = 0.80 (t, J = 
7.2 Hz, 3H), 1.11–1.22 (m, 1H), 1.26–1.40 (m, 2H), 1.42–1.52 (m, 1H), 2.65 (dddd, J 
= 9.4, 9.4, 3.2, 3.2 Hz, 1H), 3.72 (ddd, J = 9.8, 9.8, 5.2 Hz, 1H), 3.79 (s, 3H), 4.59 
(dd, J =12.4, 9.6 Hz, 1H), 4.67 (dd, J =12.4, 5.2 Hz, 1H), 6.84–6.88 (m, 2H), 7.06–
7.10 (m, 2H), 9.69 (d, J = 2.8 Hz, 1H). 13C NMR (100 MHz, CDCl3): δ = 14.1, 19.9, 
29.6, 42.6, 54.1, 55.4, 78.8, 114.6, 128.6, 129.2, 159.4, 203.5. 
 
(R)-2-[(S)-1-(4-Methylphenyl)-2-nitroethyl]pentanal (9j). 
Obtained in nearly quantitative yield with a dr 93/7 and 92% ee (entry 10, table 2). 
Eluent for residue purification Et2O/hexanes 1:6. Chromatographic and spectroscopic 
data are in accordance with those previously reported.20 Chiral HPLC analysis: 
Chiralpak® IC column, hexane/iPrOH 90:10, flow rate 1.0 mL min–1, λ = 220 nm, tR = 
22.5 min (minor) and 26.1 min (major). 1H NMR (400 MHz, CDCl3): δ = 0.80 (t, J = 
7.0 Hz, 3H), 1.10–1.23 (m, 1H), 1.24–1.40 (m, 2H), 1.42–1.53 (m, 1H), 2.32 (s, 3H), 
2.67 (dddd, J = 9.4, 9.4, 3.2, 3.2 Hz, 1H), 3.73 (ddd, J = 9.6, 9.6, 5.2 Hz, 1H), 4.61 
(dd, J = 12.8, 9.6 Hz, 1H), 4.68 (dd, J = 12.8, 5.2 Hz, 1H), 7.03–7.06 (m, 2H), 7.13–
7.16 (m, 2H), 9.69 (d, J = 2.8 Hz, 1H). 13C NMR (100 MHz, CDCl3): δ = 14.0, 19.9, 
21.2, 29.6, 43.0, 54.0, 128.0, 129.9, 133.8, 138.0, 203.5. 
 
(R)-2-[(S)-1-(4-Chlorophenyl)-2-nitroethyl]pentanal (9k). 
Obtained in nearly quantitative yield with a dr 92/8 and 91% ee (entry 11, table 2). 
Eluent for residue purification Et2O/hexanes 1:3. Chromatographic and spectroscopic 
data are in accordance with those previously reported.24 Chiral HPLC analysis: 
Chiralpak® IC column, hexane/iPrOH 90:10, flow rate 1.0 mL min–1, λ = 220 nm, tR = 
28.8 min (minor) and 30.6 min (major). 1H NMR (400 MHz, CDCl3): δ = 0.80 (t, J = 
7.2 Hz, 3H), 1.11–1.23 (m, 1H), 1.24–1.40 (m, 2H), 1.42–1.51 (m, 1H), 2.68 (dddd, J 
= 9.2, 9.2, 3.4, 2.6 Hz, 1H), 3.76 (ddd, J = 9.8, 9.8, 5.0 Hz, 1H), 4.61 (dd, J = 12.8, 
10.0 Hz, 1H), 4.70 (dd, J = 12.8, 5.2 Hz, 1H), 7.10–7.14 (m, 2H), 7.30–7.34 (m, 2H), 
9.69 (d, J = 2.8 Hz, 1H). 13C NMR (100 MHz, CDCl3): δ = 14.0, 19.8, 29.6, 42.6, 53.7, 
78.3, 129.5, 129.5, 134.2, 135.5, 202.9. 
 
(R)-2-[(S)-1-(4-Bromophenyl)-2-nitroethyl]pentanal (9l). 
Obtained in 99% yield with a dr 94/6 and 92% ee (entry 12, table 2). Eluent for 
residue purification Et2O/hexanes 1:3. Chromatographic and spectroscopic data are 
in accordance with those previously reported.20 Chiral HPLC analysis: Chiralcel® OD-
H column, hexane/iPrOH 93:7, flow rate 1.0 mL min–1, λ = 220 nm, tR = 24.4 min 
(minor) and 26.7 min (major). 1H NMR (400 MHz, CDCl3): δ = 0.80 (t, J = 7.0, 3H), 
1.12–1.21 (m, 1H), 1.24–1.40 (m, 2H), 1.41–1.50 (m, 1H), 2.68 (dddd, J = 9.2, 9.2, 
3.6, 2.8 Hz, 1H), 3.75 (ddd, J = 9.8, 9.8, 4.8 Hz, 1H), 4.60 (dd, J = 12.8, 9.6 Hz, 1H), 
4.69 (dd, J = 12.8, 4.8 Hz, 1H), 7.04–7.08 (m, 2H), 7.46–7.49 (m, 2H), 9.68 (d, J = 
2.4 Hz, 1H). 13C NMR (100 MHz, CDCl3): δ = 14.0, 19.8, 29.6, 42.7, 53.6, 78.2, 
122.2, 129.8, 132.4, 136.0, 202.9. 
 
(R)-2-[(S)-1-(3-Bromophenyl)-2-nitroethyl]pentanal (9m). 
Obtained in nearly quantitative yield with a dr 95/5 and 92% ee (entry 13, table 2). 
Eluent for residue purification Et2O/hexanes 1:3. Chromatographic and spectroscopic 
data are in accordance with those previously reported.20 Chiral HPLC analysis: 
Chiralpak® IC column, hexane/iPrOH 95:5, flow rate 1.0 mL min–1, λ = 220 nm, tR = 
39.1 min (minor) and 45.1 min (major). 1H NMR (400 MHz, CDCl3): δ = 0.81 (t, J = 
7.2 Hz, 3H), 1.13–1.52 (m, 4H), 2.70 (dddd, J = 9.2, 9.2, 3.6, 2.4 Hz, 1H), 3.74 (ddd, 
J = 9.6, 9.6, 5.2 Hz, 1H), 4.62 (dd, J = 12.8, 9.6 Hz, 1H), 4.70 (dd, J = 12.8, 5.2 Hz, 
1H), 7.12 (ddd, J = 7.8, 1.8, 0.8 Hz, 1H), 7.22 (dd, J = 7.8, 7.8 Hz, 1H), 7.33 (dd, J = 
1.8, 1.8 Hz, 1H), 7.44 (ddd, J = 8.0, 2.0, 0.8 Hz, 1H), 9.69 (d, J = 2.4 Hz, 1H). 13C 
NMR (100 MHz, CDCl3): δ = 14.1, 19.8, 29.6, 42.8, 53.7, 78.1, 123.3, 126.8, 130.8, 
131.2, 131.5, 139.5, 202.8. 
 
(R)-2-[(S)-1-(2-Bromophenyl)-2-nitroethyl]pentanal (9n). 
Obtained in nearly quantitative yield with a dr 95/5 and 92% ee (entry 14, table 2). 
Eluent for residue purification Et2O/hexanes 1:6. Spectroscopic data are in 
accordance with those previously reported.20 Chiral HPLC analysis: Chiralpak® IC 
column, hexane/iPrOH/acetone 95:4:1, flow rate 1.0 mL min–1, λ = 220 nm, tR = 19.9 
min (mayor) and 20.8 min (minor). 1H NMR (400 MHz, CDCl3): δ = 0.83 (t, J = 7.0 Hz, 
3H), 1.18-1.40 (m, 4H), 2.93-3.00 (m, 1H), 4.33-4.39 (m, 1H), 4.67 (dd, J = 13.2, 4.8 
Hz, 1H), 4.86 (dd, J = 13.2, 9.2 Hz, 1H), 7.16 (ddd, J = 8.0, 7.2, 1.6 Hz, 1H), 7.21 
(dd, J = 8.0, 1.6 Hz, 1H), 7.32 (ddd, J = 8.0, 7.2, 1.2 Hz, 1H), 7.61 (dd, J = 8.0, 1.2 
Hz, 1H), 9.72 (d, J = 2.4 Hz, 1H). 13C NMR (100 MHz, CDCl3): δ =  14.1, 20.0, 29.7, 
41.9, 53.3, 76.9, 128.2, 129.0, 129.6, 131.1, 134.0, 136.4, 203.3. 
 
General procedure for the Michael reaction of ketones with β-nitroolefins 
A solution organocatalyst OC1 (0.02 mmol), and ketone (0.4 mmol) in trifluoromethyl 
benzene (2 mL) was stirred at room temperature for 10 min. The nitroolefin (0.2 
mmol) was added and stirring was continued for the required time at the same 
temperature. The reaction was concentrated in vacuo and the residue was analysed 
by 1H NMR using 1,3,5-trimethoxybenzene as internal standard16 to determine the 
reaction yield and diastereoselectivity. Purification of the residue by silica gel column 
chromatography yielded the corresponding Michael adducts. Enantioselectivity was 
determined by chiral HPLC analysis of the purified adducts using a chiral stationary 
phase.  
 
(S)-2-[(R)-2-Nitro-1-phenylethyl]cyclohexan-1-one (10a). 
Obtained in nearly quantitative yield with a dr 97/3, and 99% ee (entry 1, table 4). 
Eluent for residue purification Et2O/hexanes 1:3. Spectroscopic data are in 
accordance with those previously reported.25 Chiral HPLC analysis: Chiralpak® IA 
column, hexane/EtOH/acetone 84/15/1, flow rate 1.0 mL min–1, λ = 220 nm, tR = 9.8 
min (minor) and 16.3 min (major). [α]25D = –25.3 (c = 1.00, CHCl3) [lit. 25 [α]20D = –27.0 
(c = 1.00, CHCl3)]. 1H NMR (400 MHz, CDCl3): δ = 1.10–1.22 (m, 1H), 1.46–1.72 (m, 
4H), 1.97–2.03 (m, 1H), 2.31 (ddd, J = 12.8, 12.8, 6.0 Hz, 1H), 2.37–2.42 (m, 1H), 
2.61 (ddd, J= 11.0, 11.0, 4.8 Hz, 1H), 3.69 (ddd, J= 10.0, 10.0, 4.4 Hz, 1H), 4.55 (dd, 
J= 12.4, 10.0 Hz, 1H), 4.87 (dd, J= 12.4, 4.4 Hz, 1H), 7.08–7.26 (m, 5H). 13C NMR 
(100 MHz, CDCl3): δ = 25.1, 28.6, 33.3, 42.8, 44.0, 52.6, 79.0, 127.8, 128.3, 129.0, 
137.9, 212.0. 
 
(R)-3-[(R)-2-Nitro-1-phenylethyl]tetrahydro-4H-pyran-4-one (10b). 
Obtained in nearly quantitative yield with a dr 98/2, and 94% ee (entry 2, table 4). 
Eluent for residue purification Et2O/hexanes 2:1. Spectroscopic data are in 
accordance with those previously reported.25 Chiral HPLC analysis: Chiralpak® IA 
column, hexane/iPrOH 85/15, flow rate 1.0 mL min–1, λ = 210 nm, , tR = 16.0 min 
(minor) and 27.1 min (major). [α]25D = –37.9 (c = 1.00, CHCl3) [lit. 25 [α]25D = –27.5 (c 
= 1.00, CHCl3)]. 1H NMR (400 MHz, CDCl3): δ = 2.58 (ddd, J= 14.0, 4.0, 4.0 Hz, 1H), 
2.69 (dddd, J= 14.0, J= 9.6, 6.4, 1.2 Hz, 1H), 2.90 (dddd, J= 10.6, J= 8.8, 5.4, 1.0 Hz, 
1H), 3.29 (dd, J= 11.4, 9.0 Hz, 1H), 3.71 (ddd, J= 11.4, 5.2, 1.2 Hz, 1H), 3.79 (ddd, 
J= 11.2, 10.0, 4.0 Hz, 1H), 3.85 (ddd, J= 10.4, 10.4, 4.4 Hz, 1H), 4.16 (dddd, J= 11.2, 
6.4, 4.0, 1.2 Hz, 1H), 4.67 (dd, J= 12.6, 10.2 Hz, 1H), 4.95 (dd, J= 12.6, 4.4 Hz, 1H), 
4.19–4.38 (m, 5H). 13C NMR (100 MHz, CDCl3): δ = 41.5, 43.1, 53.4, 69.1, 71.7, 78.8, 
128.0, 128.4, 129.4, 136.4, 207.5. 
 
(R)-1-Acetyl-3-[(R)-2-nitro-1-phenylethyl]piperidin-4-one (10c). 
Obtained in 90% yield with a dr 85/15, and 91% ee (entry 3, table 4). Eluent for 
residue purification EtOAc. Spectroscopic data are in accordance with those 
previously reported.26 Chiral HPLC analysis: Chiralpak® IA column, 
hexane/EtOH/acetone 92/7/1, flow rate 1.5 mL min–1, λ = 210 nm, tR = 58.1 min 
(minor) and 61.7 min (major). [α]25D = +12.9 (c = 1.00, CH2Cl2) [lit. 26 [α]D = +20.9 (c = 
1.00, CH2Cl2). 1H NMR (300 MHz, toluene-d8, 353 K): δ = 1.55 (s, 3H), 1.95–2.08 (m, 
2H), 2.24–2.47 (m, 2H), 2.61–2.73 (m, 1H), 2.94–4.20 (m, 2H), 3.51–3.72 (m, 1H), 
4.26 (dd, J = 12.6, 9.3 Hz, 1H), 4.63 ((dd, J= 12.6, 5.0 Hz, 1H) , 6.92–7.08 (m, 5H). 
13C NMR (75 MHz, toluene-d8, 353 K): δ = 20.5, 41.3, 42.4, 43.6 , 47.4 , 52.2, 78.7, 
128.1, 128.6, 129.3, 138.0, 168.3, 206.4. 
 
(S)-2-[(S)-1-(Furan-2-yl)-2-nitroethyl]cyclohexan-1-one (10d). 
Obtained in 96% yield with a dr 90/10, and 94% ee (entry 4, table 4). Eluent for 
residue purification Et2O/hexanes 1:3. Spectroscopic data are in accordance with 
those previously reported.25 Chiral HPLC analysis: Chiralpak® IA column, 
hexane/EtOH 90/10, flow rate 0.8 mL min–1, λ = 220 nm, tR = 24.0 min (major) and 
31.0 min (minor). [α]25D = –14.7 (c = 1.00, CHCl3) [lit.25 [α]20D = –15.4 (c = 1.00, 
CHCl3)]. 1H NMR (400 MHz, CDCl3): δ = 1.22–1.32 (m, 1H), 1.60–1.67 (m, 2H), 1.71–
1.78 (m, 1H), 1.80–1.86 (m, 1H), 2.06–2.12 (m, 1H), 2.31–2.39 (m, 1H), 2.42–2.47 
(m, 1H), 2.74 (dddd, J = 12.4, 9.2, 5.4, 1.0 Hz, 1H), 3.96 (ddd, J = 9.2, 9.2, 4.8 Hz, 
1H), 4.65 (dd, J = 12.4, 9.6 Hz, 1H), 4.78 (dd, J = 12.4, 4.8 Hz, 1H), 6.17 (dd, J = 3.2, 
0.4 Hz, 1H), 6.27 (dd, J = 3.2, 2.0 Hz, 1H) , 7.33 (dd, J = 2.0, 0.6 Hz, 1H). 13C NMR 
(100 MHz, CDCl3): δ = 25.2, 28.3, 32.6, 37.7, 42.7, 51.2, 76.8, 109.1, 110.4, 142.4, 
151.0, 211.0. 
 
(S)-2-[(R)-1-(4-Methoxyphenyl)-2-nitroethyl]cyclohexan-1-one (10e). 
Obtained in nearly quantitative yield with a dr 96/4, and 84% ee (entry 5, table 4). 
Eluents for residue purification Et2O/hexanes 1:3 and after Et2O/hexanes 1:1. 
Spectroscopic data are in accordance with those previously reported.25 Chiral HPLC 
analysis: Chiralpak® IA column, hexane/iPrOH 95/5, flow rate 1.0 mL min–1, λ = 220 
nm, tR = 18.8 min (minor) and 22.0 min (major). [α]25D = –21.9 (c = 1.00, CHCl3) [lit. 25 
[α]20D = –25.1 (c = 1.00, CHCl3)]. 1H NMR (400 MHz, CDCl3): δ = 1.16–1.26 (m, 1H), 
1.53–1.79 (m, 4H), 2.02–2.10 (m, 1H), 2.36 (dddd, J = 12.8, 12.8, 6.0, 0.8 Hz, 1H), 
2.45 (dddd, J = 12.8, 4.0, 4.0, 1.2 Hz, 1H), 2.60–2.67 (m. 1H), 3.70 (ddd, J = 10.0, 
10.0, 4.4 Hz, 1H), 3.76 (s, 3H), 4.56 (dd, J = 12.4, 10.0 Hz, 1H), 4.90 (dd, J = 12.4, 
4.4 Hz, 1H), 6.81–6.85 (m, 2H), 7.05–7.09 (m, 2H). 13C NMR (100 MHz, CDCl3): δ = 
25.1, 28.6, 33.2, 42.8, 43.3, 52.7, 55.3, 79.2, 114.4, 129.3, 129.6, 159.1, 212.2. 
 
(S)-2-[(R)-1-(4-Methylphenyl)-2-nitroethyl]cyclohexan-1-one (10f). 
Obtained in nearly quantitative yield with a dr 98/2, and 96% ee (entry 6, table 4). 
Eluent for residue purification Et2O/hexanes 1:3. Chromatographic and spectroscopic 
data are in accordance with those previously reported.27 Chiral HPLC analysis: 
Chiralpak® AS-H column, hexane/iPrOH 90/10, flow rate 1.0 mL min–1, λ = 220 nm, tR 
= 11.1 min (minor) and 18.3 min (major). 1H NMR (400 MHz, CDCl3): δ = 1.23 (dddd, 
J = 12.4, 12.4, 12.4, 3.6 Hz, 1H), 1.51–1.81 (m, 4H), 2.03–2.11 (m, 1H), 2.31 (s, 3H), 
2.38 (dddd, J = 12.4, 12.4, 6.0, 1.0 Hz, 1H), 2.47 (dddd, J = 12.8, 4.8, 3.4, 1.2, 1H), 
2.66 (dddd, J = 12.0, 10.0, 4.8, 0.8Hz , 1H), 3.72 (ddd, J = 10.0, 10.0, 4.8 Hz, 1H), 
4.60 (dd, J = 12.4, 10.0 Hz, 1H), 4.91 (dd, J = 12.4, 4.4H, 1H), 7.03–7.06 (m, 2H), 
7.10–7.13 (m, 2H). 13C NMR (100 MHz, CDCl3): δ = 21.2, 25.1, 28.7, 33.3, 42.9, 
43.7, 52.7, 79.1, 128.1, 129.7, 134.7, 137.6, 212.2. 
 
(S)-2-[(R)-1-(4-Chlorophenyl)-2-nitroethyl]cyclohexan-1-one (10g). 
Obtained in nearly quantitative yield with a dr 95/5, and 98% ee (entry 7, table 4). 
Eluent for residue purification Et2O/hexanes 1:3. Chromatographic and spectroscopic 
data are in accordance with those previously reported.27 Chiral HPLC analysis: 
Chiralpak® AS-H column, hexane/iPrOH 90/10, flow rate 1.0 mL min–1, λ = 220 nm, tR 
= 14.8 min (minor) and 24.1 min (major). 1H NMR (400 MHz, CDCl3): δ = 1.17–1.27 
(m, 1H), 1.51–1.75 (m, 3H), 1.76–1.82 (m, 1H), 2.05–2.12 (m, 1H), 2.37 (dddd, J = 
12.8, 12.8, 6.0, 0.8 Hz, 1H), 2.47 (dddd, J = 12.8, 4.6, 3.4, 1.4 Hz, 1H), 2.64 (dddd, J 
= 12.2, 9.6, 5.0, 0.8 Hz, 1H), 3.75 (ddd, J = 9.8, 9.8, 4.6 Hz, 1H), 4.59 (dd, J = 12.8, 
10.0 Hz, 1H), 4.93 (dd, J = 12.8, 4.6 Hz, 1H), 7.09–7.13 (m, 2H), 7.28–7.31 (m, 2H). 
13C NMR (100 MHz, CDCl3): δ = 25.2, 28.6, 33.3, 42.9, 43.5, 52.5, 78.7, 129.3, 
129.7, 133.8, 136.4, 211.6. 
 
(S)-2-[(R)-1-(4-Bromophenyl)-2-nitroethyl]cyclohexan-1-one (10h). 
Obtained in nearly quantitative yield with a dr 96/4, and 93% ee (entry 8, table 4). 
Eluents for residue purification Et2O/hexanes 1:3 and after Et2O/hexanes 1:1. 
Spectroscopic data are in accordance with those previously reported.25 Chiral HPLC 
analysis: Chiralpak® IA column, hexane/iPrOH 90/10, flow rate 1.0 mL min–1, λ = 220 
nm, tR = 14.0 min (minor) and 20.4 min (major). [α]25D = –12.9 (c = 1.00, CHCl3) [lit.25 
[α]20D = –15.4 (c = 1.00, CHCl3)]. 1H NMR (400 MHz, CDCl3): δ = 1.22 (dddd, J = 
12.4, 12.4, 12.4, 3.2 Hz, 1H), 1.53–1.73 (m, 3H), 1.76–1.81 (m, 1H), 2.06–2.11 (m, 
1H), 2.36 (ddd, J = 12.4, 12.4, 5.6 Hz, 1H), 2.44–2.48 (m, 1H), 2.61–2.67 (m, 1H), 
3.74 (ddd, J = 10.0, 10.0, 4.4 Hz, 1H), 4.59 (dd, J = 12.4, 10.0 Hz, 1H), 4.92 (dd, J = 
12.4, 4.4 Hz, 1H), 7.04–7.07 (m, 2H), 7.43–7.46 (m, 2H).13C NMR (100 MHz, CDCl3): 
δ = 25.2, 28.5, 33.3, 42.9, 43.5, 52.4, 78.6, 121.8, 130.0, 132.2, 136.9, 211.6. 
 
(S)-2-[(R)-1-(3-Bromophenyl)-2-nitroethyl]cyclohexan-1-one (10i). 
Obtained in nearly quantitative yield with a dr 95/5, and 93% ee (entry 9, table 4). 
Eluent for residue purification Et2O/hexanes 1:3. Chromatographic and spectroscopic 
data are in accordance with those previously reported.28 Chiral HPLC analysis: 
Chiralpak® AS-H column, hexane/iPrOH 80/20, flow rate 1.0 mL min–1, λ = 220 nm, tR 
= 11.4 min (minor) and 21.6 min (major). 1H NMR (400 MHz, CDCl3): δ = 1.23 (dddd, 
J = 12.2, 12.2, 12.2, 3.4 HZ, 1H), 1.52–1.66 (m, 2H), 1.67–1.75 (m, 1H), 1.78–1.83 
(m, 1H), 2.05–2.13 (m, 1H), 2.37 (dddd, J = 12.8, 12.8, 6.0, 0.8 Hz, 1H), 2.47 (dddd, 
J = 12.8, 4.6, 3.6, 1.6 Hz, 1H), 2.65 (dddd, J = 12.4, 9.8, 5.0, 0.8 Hz, 1H), 3.74 (ddd, 
J = 10.0, 10.0, 4.8 Hz, 1H), 4.60 (dd, J = 12.8, 10.0 Hz, 1H), 4.93 (dd, J = 12.8, 4.8 
Hz, 1H), 7.11 (ddd, J = 7.6, 1.2, 1.2 Hz, 1H), 7.19 (dd, J = 7.8, 7.8 Hz, 1H), 7.32 (dd, 
J = 1.8, 1.8 Hz, 1H), 7.40 (ddd, J = 7.8, 2.0, 1.2 Hz, 1H).13C NMR (100 MHz, CDCl3): 
δ = 25.2, 28.6, 33.4, 42.9, 43.8, 52.5, 78.5, 123.1, 127.1, 130.6, 131.1, 131.3, 140.4, 
211.5. 
 
(S)-2-[(R)-1-(2-Bromophenyl)-2-nitroethyl]cyclohexan-1-one (10j). 
Obtained in nearly quantitative yield with a dr 97/3, and 94% ee (entry 10, table 4). 
Eluent for residue purification Et2O/hexanes 1:3. Spectroscopic data are in 
accordance with those previously reported.29 [α]25D = –40.7 (c = 0.75, CHCl3) [lit.29 
[α]20D = –50.8 (c = 1.00, CHCl3)]. Chiral HPLC analysis: Chiralpak® IC column, 
hexane/iPrOH 90/10, flow rate 1.0 mL min–1, λ = 220 nm, tR = 28.3 min (major) and 
33.5 min (minor). 1H NMR (400 MHz, CDCl3): δ = 1.32-1.42 (m, 1H), 1.53-1.77 (m, 
3H), 1.78-1.84 (m, 1H), 2.06-2.14 (m, 1H), 2.38 (dddd, J = 12.8, 12.8, 6.0, 0.8 Hz, 
1H), 2.47 (dddd, J = 12.8, 4.6, 3.2, 1.4 Hz, 1H), 2.82-2.96 (m, 1H), 4.27s-4.34 (m, 
1H), 4.85-4.94 (m, 2H), 7.12 (ddd, J = 8.0, 7.4, 1.8 Hz, 1H), 7.21 (dd, J = 7.6, 1.6 HZ, 
1H), 7.29 (ddd, J = 7.6, 7.6, 1.2 Hz, 1H), 7.57 (dd, J = 8.0, 1.2 Hz, 1H). 13C NMR 
(100 MHz, CDCl3): δ = 25.4, 28.6, 33.1, 42.9, 43.0 (from HSQC), 52.2 (from HSQC), 
77.5, 128.1, 129.2, 133.8, 137.4, 211.7. 
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